Latest news - Novo Nordisk
Dec 15, 2024 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Novo Nordisk A/S: CagriSema demonstrates superior weight
6 days ago · Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
6 days ago · Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
6 days ago · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
News Details - novonordisk.com
Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Company announcements & press releases - Novo Nordisk
Press releases are intended for the media. Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
Novo Nordisk U.S. News & Media Hub | Novo Nordisk U.S.
View financial meetings and events, strategic aspirations for 2025 and contact information for investor relations. A place to find different points of view from inside Novo Nordisk and the communities we serve. Welcome to Novo Nordisk's U.S. news and media hub.
Novo Nordisk’s next-generation weight-loss drug CagriSema
5 days ago · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...
Novo Nordisk shares tumble as data on weight-loss drug trial …
6 days ago · Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.